The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.
A new analysis evaluated the economic implications of alopecia on women and their families, with significant out-of-pocket expenses attributed to treatments and measures to conceal the condition.